Award
NIH Reporter #PAR-22-216
Immune Checkpoint Blockade Targeting the Novel PSGL-1/VISTA Axis for Pancreatic Cancer
Recipient
National Cancer Institute (NCI)
Award Amount
$209,674.00
Ceiling
$209,674.00
Awarded
February 26, 2026
Identifier
PAR-22-216
A multi-year NIH grant awarded by the National Cancer Institute to develop immunotherapy targeting the PSGL-1/VISTA axis for pancreatic cancer, focusing on overcoming resistance to immune checkpoint therapies.
Description
The project focuses on developing immunotherapy targeting PSGL-1/VISTA axis for pancreatic cancer. The award is a multi-year grant with a focus on immune checkpoint blockade research. The project involves preclinical models and potential clinical translation. The project aims to address resistance to immune checkpoint therapies in pancreatic ductal adenocarcinoma (PDAC).